Digest Network Come funziona
Network
/
Società
As
Non verificato

AstraZeneca

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

87 comunicati stampa

Guarda tutti i comunicati
04/12/2025
Eventi
Biotecnologia
Sanità
Farmaceutica
Salute
AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH
Fonte
AstraZeneca
Emittente
Business Wire
1.00
0
02/12/2025
Scienza
Cardiologia
Biotecnologia
Farmaceutica
Sanità
Salute
Igiene alimentare
Industria
Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension
Fonte
AstraZeneca
Emittente
Business Wire
1.00
0
26/11/2025
Eventi
Industria
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Farmaceutica
Biotecnologia
IMFINZI® approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers
Fonte
AstraZeneca
Emittente
Business Wire
1.00
0
21/11/2025
Industria
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth
Fonte
AstraZeneca
Emittente
Business Wire
1.00
0
09/11/2025
Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial
Fonte
AstraZeneca
Emittente
Business Wire
1.00
0
07/11/2025
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease
Fonte
AstraZeneca
Emittente
Business Wire
1.00
0
06/11/2025
Biotecnologia
Farmaceutica
Salute
Mercato azionario
AstraZeneca's 9M and Q3 2025 Financial Results
Fonte
AstraZeneca
Emittente
Business Wire
1.00
0
19/10/2025
Oncologia
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Eventi
Industria
DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option
Fonte
AstraZeneca
Emittente
Business Wire
1.00
0
18/10/2025
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Oncologia
Eventi
Industria
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial
Fonte
AstraZeneca
Emittente
Business Wire
1.00
0
17/10/2025
Multimedialità
Biotecnologia
Igiene alimentare
Salute
Vetrine/Shopping
Sanità
Farmaceutica
Scienza
Giovani
Medicina - Varie
Industria
TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps
Fonte
AstraZeneca
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0